A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Crohn's Disease
Interventions
DRUG

CP-690,550

administration via oral route twice daily

DRUG

CP-690,550

administration via oral route twice daily

DRUG

CP-690,550

administration via oral route twice daily

DRUG

Placebo

administration via oral route twice daily

Trial Locations (72)

1200

Pfizer Investigational Site, Brussels

2193

Pfizer Investigational Site, Johannesburg

3000

Pfizer Investigational Site, Leuven

4001

Pfizer Investigational Site, Durban

4004

Pfizer Investigational Site, Debrecen

4091

Pfizer Investigational Site, Durban

5600

Pfizer Investigational Site, Békéscsaba

5701

Pfizer Investigational Site, Gyula

7100

Pfizer Investigational Site, Szekszárd

7400

Pfizer Investigational Site, Kaposvár

7708

Pfizer Investigational Site, Cape Town

9000

Pfizer Investigational Site, Ghent

9023

Pfizer Investigational Site, Győr

11021

Pfizer Investigational Site, Great Neck

15241

Pfizer Investigational Site, Upper Saint Clair

15243

Pfizer Investigational Site, Pittsburgh

16635

Pfizer Investigational Site, Duncansville

20006

Pfizer Investigational Site, Washington D.C.

20815

Pfizer Investigational Site, Chevy Chase

21204

Pfizer Investigational Site, Towson

25304

Pfizer Investigational Site, Charleston

28144

Pfizer Investigational Site, Salisbury

28209

Pfizer Investigational Site, Charlotte

28210

Pfizer Investigational Site, Charlotte

28211

Pfizer Investigational Site, Charlotte

28922

Pfizer Investigational Site, Majadahonda

32207

Pfizer Investigational Site, Jacksonville

32256

Pfizer Investigational Site, Jacksonville

32605

Pfizer Investigational Site, Gainesville

32607

Pfizer Investigational Site, Gainesville

33428

Pfizer Investigational Site, Boca Raton

33442

Pfizer Investigational Site, Boca Raton

33486

Pfizer Investigational Site, Boca Raton

33496

Pfizer Investigational Site, Boca Raton

33604

Pfizer Investigational Site, Pessac

33709

Pfizer Investigational Site, St. Petersburg

35233

Pfizer Investigational Site, Birmingham

36617

Pfizer Investigational Site, Mobile

37205

Pfizer Investigational Site, Nashville

37620

Pfizer Investigational Site, Bristol

37660

Pfizer Investigational Site, Kingsport

40138

Pfizer Investigational Site, Bologna

40202

Pfizer Investigational Site, Louisville

45415

Pfizer Investigational Site, Dayton

48098

Pfizer Investigational Site, Troy

50012

Pfizer Investigational Site, Hradec Králové

54511

Pfizer Investigational Site, Vandœuvre-lès-Nancy

55905

Pfizer Investigational Site, Rochester

59037

Pfizer Investigational Site, Lille

60637

Pfizer Investigational Site, Chicago

65265

Pfizer Investigational Site, Mexico

67208

Pfizer Investigational Site, Wichita

75235

Pfizer Investigational Site, Dallas

80033

Pfizer Investigational Site, Wheat Ridge

80215

Pfizer Investigational Site, Lakewood

80304

Pfizer Investigational Site, Boulder

94901

Pfizer Investigational Site, Nitra

98195

Pfizer Investigational Site, Seattle

75390-8887

Pfizer Investigational Site, Dallas

401 13

Pfizer Investigational Site, Ústí nad Labem

00152

Pfizer Investigational Site, Roma

1105 AZ

Pfizer Investigational Site, Amsterdam

20-954

Pfizer Investigational Site, Lublin

10-561

Pfizer Investigational Site, Olsztyn

50-556

Pfizer Investigational Site, Wroclaw

826 06

Pfizer Investigational Site, Bratislava

811 07

Pfizer Investigational Site, Bratislava

Unknown

Pfizer Investigational Site, Durbanvilee

08036

Pfizer Investigational Site, Barcelona

08907

Pfizer Investigational Site, L'Hospitalet de Llobregat

BS2 8HW

Pfizer Investigational Site, Bristol

M6 8HD

Pfizer Investigational Site, Salford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT00615199 - A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease | Biotech Hunter | Biotech Hunter